Endogenous cardioprotective strategies

Abhiram Prasad, Bernard John Gersh

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The field of cardioprotection to reduce reperfusion injury has been characterized by a plethora of experimental studies with multiple pharmacological agents that have shown great promise in the laboratory, but have lacked clinical efficacy. This has led to diminishing enthusiasm for the translation of cardioprotection into clinical practice. In contrast, the field of endogenous cardiac protection is particularly appealing given that early clinical studies have documented feasibility and efficacy. Strategies for endogenous cardioprotection include ischemic preconditioning, ischemic postconditioning, and remote ischemic conditioning. However, the clinical trials performed to date have been small, used surrogate endpoints, and had strict inclusion and exclusion criteria. Larger trials are needed that will allow assessment of the applicability to a wider patient population with prior infarcts, prior revascularization, reduced ejection fraction, history of congestive heart failure, use of multiple pharmacological agents, and presence of multiple coexisting diseases. Moreover, understanding the mechanisms for the apparent benefit may lead to the development of new drugs and molecules that could target the fundamental processes of ischemia-reperfusion injury.

Original languageEnglish (US)
Title of host publicationManagement of Myocardial Reperfusion Injury
PublisherSpringer-Verlag London Ltd
Pages239-260
Number of pages22
Volume9781849960199
ISBN (Print)9781849960199, 1849960186, 9781849960182
DOIs
StatePublished - Nov 1 2013

Fingerprint

Reperfusion Injury
Ischemic Postconditioning
Pharmacology
Ischemic Preconditioning
Heart Failure
Biomarkers
Clinical Trials
Pharmaceutical Preparations
Population
Clinical Studies

Keywords

  • Postconditioning
  • Preconditioning
  • Reperfusion injury

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Prasad, A., & Gersh, B. J. (2013). Endogenous cardioprotective strategies. In Management of Myocardial Reperfusion Injury (Vol. 9781849960199, pp. 239-260). Springer-Verlag London Ltd. https://doi.org/10.1007/978-1-84996-019-9_11

Endogenous cardioprotective strategies. / Prasad, Abhiram; Gersh, Bernard John.

Management of Myocardial Reperfusion Injury. Vol. 9781849960199 Springer-Verlag London Ltd, 2013. p. 239-260.

Research output: Chapter in Book/Report/Conference proceedingChapter

Prasad, A & Gersh, BJ 2013, Endogenous cardioprotective strategies. in Management of Myocardial Reperfusion Injury. vol. 9781849960199, Springer-Verlag London Ltd, pp. 239-260. https://doi.org/10.1007/978-1-84996-019-9_11
Prasad A, Gersh BJ. Endogenous cardioprotective strategies. In Management of Myocardial Reperfusion Injury. Vol. 9781849960199. Springer-Verlag London Ltd. 2013. p. 239-260 https://doi.org/10.1007/978-1-84996-019-9_11
Prasad, Abhiram ; Gersh, Bernard John. / Endogenous cardioprotective strategies. Management of Myocardial Reperfusion Injury. Vol. 9781849960199 Springer-Verlag London Ltd, 2013. pp. 239-260
@inbook{ac9fce0ffe6e4080b0d810e75886faf5,
title = "Endogenous cardioprotective strategies",
abstract = "The field of cardioprotection to reduce reperfusion injury has been characterized by a plethora of experimental studies with multiple pharmacological agents that have shown great promise in the laboratory, but have lacked clinical efficacy. This has led to diminishing enthusiasm for the translation of cardioprotection into clinical practice. In contrast, the field of endogenous cardiac protection is particularly appealing given that early clinical studies have documented feasibility and efficacy. Strategies for endogenous cardioprotection include ischemic preconditioning, ischemic postconditioning, and remote ischemic conditioning. However, the clinical trials performed to date have been small, used surrogate endpoints, and had strict inclusion and exclusion criteria. Larger trials are needed that will allow assessment of the applicability to a wider patient population with prior infarcts, prior revascularization, reduced ejection fraction, history of congestive heart failure, use of multiple pharmacological agents, and presence of multiple coexisting diseases. Moreover, understanding the mechanisms for the apparent benefit may lead to the development of new drugs and molecules that could target the fundamental processes of ischemia-reperfusion injury.",
keywords = "Postconditioning, Preconditioning, Reperfusion injury",
author = "Abhiram Prasad and Gersh, {Bernard John}",
year = "2013",
month = "11",
day = "1",
doi = "10.1007/978-1-84996-019-9_11",
language = "English (US)",
isbn = "9781849960199",
volume = "9781849960199",
pages = "239--260",
booktitle = "Management of Myocardial Reperfusion Injury",
publisher = "Springer-Verlag London Ltd",

}

TY - CHAP

T1 - Endogenous cardioprotective strategies

AU - Prasad, Abhiram

AU - Gersh, Bernard John

PY - 2013/11/1

Y1 - 2013/11/1

N2 - The field of cardioprotection to reduce reperfusion injury has been characterized by a plethora of experimental studies with multiple pharmacological agents that have shown great promise in the laboratory, but have lacked clinical efficacy. This has led to diminishing enthusiasm for the translation of cardioprotection into clinical practice. In contrast, the field of endogenous cardiac protection is particularly appealing given that early clinical studies have documented feasibility and efficacy. Strategies for endogenous cardioprotection include ischemic preconditioning, ischemic postconditioning, and remote ischemic conditioning. However, the clinical trials performed to date have been small, used surrogate endpoints, and had strict inclusion and exclusion criteria. Larger trials are needed that will allow assessment of the applicability to a wider patient population with prior infarcts, prior revascularization, reduced ejection fraction, history of congestive heart failure, use of multiple pharmacological agents, and presence of multiple coexisting diseases. Moreover, understanding the mechanisms for the apparent benefit may lead to the development of new drugs and molecules that could target the fundamental processes of ischemia-reperfusion injury.

AB - The field of cardioprotection to reduce reperfusion injury has been characterized by a plethora of experimental studies with multiple pharmacological agents that have shown great promise in the laboratory, but have lacked clinical efficacy. This has led to diminishing enthusiasm for the translation of cardioprotection into clinical practice. In contrast, the field of endogenous cardiac protection is particularly appealing given that early clinical studies have documented feasibility and efficacy. Strategies for endogenous cardioprotection include ischemic preconditioning, ischemic postconditioning, and remote ischemic conditioning. However, the clinical trials performed to date have been small, used surrogate endpoints, and had strict inclusion and exclusion criteria. Larger trials are needed that will allow assessment of the applicability to a wider patient population with prior infarcts, prior revascularization, reduced ejection fraction, history of congestive heart failure, use of multiple pharmacological agents, and presence of multiple coexisting diseases. Moreover, understanding the mechanisms for the apparent benefit may lead to the development of new drugs and molecules that could target the fundamental processes of ischemia-reperfusion injury.

KW - Postconditioning

KW - Preconditioning

KW - Reperfusion injury

UR - http://www.scopus.com/inward/record.url?scp=84930013921&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930013921&partnerID=8YFLogxK

U2 - 10.1007/978-1-84996-019-9_11

DO - 10.1007/978-1-84996-019-9_11

M3 - Chapter

AN - SCOPUS:84930013921

SN - 9781849960199

SN - 1849960186

SN - 9781849960182

VL - 9781849960199

SP - 239

EP - 260

BT - Management of Myocardial Reperfusion Injury

PB - Springer-Verlag London Ltd

ER -